Double-hit lymphomas: current paradigms and novel treatment approaches
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Double-hit lymphomas: current paradigms and novel treatment approaches
Authors
Keywords
-
Journal
Hematology-American Society of Hematology Education Program
Volume 2014, Issue 1, Pages 107-112
Publisher
American Society of Hematology
Online
2014-11-25
DOI
10.1182/asheducation-2014.1.107
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
- (2014) D. W. Scott et al. BLOOD
- MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
- (2014) Anamarija M. Perry et al. BRITISH JOURNAL OF HAEMATOLOGY
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience
- (2014) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma
- (2014) Joydeep Bhadury et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers
- (2014) A Sheth et al. Cell Death & Disease
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
- (2013) Z. Zhou et al. BLOOD
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- (2013) Jakob Lovén et al. CELL
- MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations
- (2013) Mette Ø. Pedersen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
- (2013) S. M. Aukema et al. HAEMATOLOGICA
- SIRT4 Protein Suppresses Tumor Formation in Genetic Models of Myc-induced B Cell Lymphoma
- (2013) Seung Min Jeong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
- (2013) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
- (2013) David Cunningham et al. LANCET
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Low-Intensity Therapy in Adults with Burkitt's Lymphoma
- (2013) Kieron Dunleavy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
- (2013) B Tolani et al. ONCOGENE
- PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
- (2013) M. Pfeifer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
- (2012) Roland Schmitz et al. NATURE
- Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing
- (2012) NATURE GENETICS
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype
- (2011) W. H. Wilson et al. HAEMATOLOGICA
- B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome
- (2011) Shaoying Li et al. MODERN PATHOLOGY
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Double-hit B-cell lymphomas
- (2010) S. M. Aukema et al. BLOOD
- A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
- (2010) Leandro C. Cerchietti et al. CANCER CELL
- Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
- (2010) Sharon Barrans et al. JOURNAL OF CLINICAL ONCOLOGY
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
- (2009) K. Dunleavy et al. BLOOD
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
- (2009) N. A. Johnson et al. BLOOD
- MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
- (2009) K. J. Savage et al. BLOOD
- A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
- (2008) G. M. Mead et al. BLOOD
- Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
- (2008) Wyndham H. Wilson et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
- (2008) W Klapper et al. LEUKEMIA
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
- (2008) G. Lenz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now